Novartis and Bristol-Myers Squibb collaborate for developing a cancer-combo treatment

Most experts believe that combining immunotherapies with existing treatment options such as chemotherapies, radiation, targeted cancer therapies (and importantly also with cancer vaccines, many of which are currently under development) holds great potential and several collaborations have recently been announced pursuing this strategy.

A few days ago, a new effort do developing these combination therapies has been announced by Novartis and Bristol-Myers Squibb: The two companies will set-up a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of combining Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) with three molecularly targeted oncology therapies (Zykadia (ceritinib), INC280 and EGF816) from Novartis. Novartis will conduct two Phase 1/2 studies focused on non-small cell lung cancer (NSCLC). Financial details were not disclosed.

of Novartis